Search

Displaying results 2401 - 2410 of 8469 in total
  1. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures

  2. Drug

    Sertaconazole

    go.drugbank.com/drugs/DB01153
    Approved

    It is available in topical formulations for the treatment of skin infections such as athlete's foot.

  3. Drug

    Parachlorophenol

    go.drugbank.com/drugs/DB13154
    ApprovedWithdrawn

    P-chlorophenol is a white crystals with a strong phenol odor. Slightly soluble to soluble in water, depending on the isomer, and denser than water. Noncombustible.

  4. Drug

    Antihemophilic factor (recombinant), PEGylated

    go.drugbank.com/drugs/DB09329
    ApprovedInvestigational

    Antihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label].

  5. Drug

    Revakinagene taroretcel

    go.drugbank.com/drugs/DB05344
    ApprovedInvestigational

    [L52540] It has also been investigated in glaucoma,[A265115] retinitis pigmentosa (RP), and age-related macular degeneration.[A265125]

  6. Drug

    Angiotensin II

    go.drugbank.com/drugs/DB11842
    ApprovedInvestigational

    As of December 21, 2017 the FDA approved La Jolla Pharmaceutical's Giapreza (angiotensin II) Injection for Intravenouse Infusion for the indication of acting as a vasoconstrictor to increase blood pressure … Angiotensin II has been investigated for the treatment, basic science, and diagnostic of Hypertension, Renin Angiotensin System, and Idiopathic Membranous Nephropathy.

  7. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    or as an alternative to erythromycin treatment [A176170]. … This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia [L5737].

  8. Drug

    Dichloroacetic acid

    go.drugbank.com/drugs/DB08809
    ApprovedInvestigationalWithdrawn

    DCA was approved for use in Canada in 1989 (as a topical formulation for treatment of warts and for cauterization and removal of a wide variety of skin and tissue lesions), but was cancelled post market … Salts of DCA are used as drugs since they inhibit the enzyme pyruvate dehydrogenase kinase.

  9. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  10. Drug

    Nimesulide

    go.drugbank.com/drugs/DB04743
    ApprovedWithdrawn

    Due to concerns about the risk of hepatotoxicity, nimesulide has been withdrawn from market in many countries.